Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (TheStreet) -- STOCK COMMENTS / EPS CHANGES
Apollo Group (APOL) estimates, target were raised at Goldman Sachs. Shares now seen reaching $62. Estimates also increased on better than expected enrollment and revenue, Goldman said. Buy rating.Apollo Group estimates changed through 2012 at UBS. Fourth-quarter new starts guidance was worse than expected, UBS said. Maintain Neutral rating and $42 price target. Apollo Group price target raised to $47 at FBR Capital Markets. Company is making progress toward improving student outcomes, FBR said. CareFusion (CFN) estimates, target lowered at UBS. Shares now seen reaching $31. Estimates also lowered, on lower revenues from respiratory and dispensing, UBS said. Buy rating. Colfax (CFX) price target was boosted to $30 at Bank of America/Merrill Lynch. Company is leveraged to a turn in the power generation cycle, BofA/Merrill said. Buy rating. Cablevision (CVC) estimates, target cut at Goldman Sachs. Shares now seen reaching $25. Estimates also lowered on slower growth, Goldman said. Neutral rating. DeVry (DV) target raised at Citigroup. Price target increased to $64 on attractive fundamentals, diversified revenue mix and low regulatory exposure, Citigroup said. Maintain Buy rating. Forest City (FCE) estimates changed through 2013 at Goldman Sachs. Near-term growth profile lags peers, Goldman said. Maintain Neutral rating and $18 price target. First Solar (FSLR) estimates, target raised at UBS. Shares now seen reaching $170. Estimates also increased, on substantial EPS visibility, UBS said. Buy rating. Juniper (JNPR) estimates, target cut at Barclays. Shares now seen reaching $47. Estimates also lowered on a switching dip and sluggish Japan, Barclays said. Overweight rating. Lam Research (LRCX) numbers were cut through 2012 at Credit Suisse. Expect lower CapEx spending across the industry, Credit Suisse said. Outperform rating and new $60 price target. Marathon Oil (MRO) estimates, target cut at UBS. Shares now seen reaching $40. Estimates also lowered to reflect the completion of the downstream spin-off, UBS said. Buy rating.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV